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FUNCTIONAL HETEROGENEITY OF FIBROBLASTS IN DERMAL WOUND
HEALING
Ehsan A. Ehsanipour, M.S.
Advisory Professor: Raghu Kalluri, M.D., Ph.D.

Impaired wound healing can lead to excessive scarring, dehiscence, chronic
ulcers, and infection, which have adverse impact on the quality of life and pose a
significant economic burden on the health care system. Thus, new therapeutic
approaches are critically important. Dermal fibroblasts are critical players in cutaneous
wound healing, possibly lending their contractile properties and extracellular matrix
(ECM) remodeling functions to promote effective tissue repair. Dermal fibroblasts are
also postulated to orchestrate tissue repair by interacting with and controlling other
cell types in the wound microenvironment. It has become increasingly clear that the
generic term “fibroblast” encompasses a diverse cell population with distinct origins
and heterogeneous functions. Fibroblast heterogeneity is in part exemplified by the
numerous expression markers used to distinguish them. The overarching goal of this
study is to precisely define the heterogeneity of dermal fibroblasts and unravel their
functional roles during cutaneous wound healing process.
In order to decipher the dynamics of fibroblast marker composition during the
wound repair process we utilized multiplexed immunolabeling platforms in order to
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quantify the expression of multiple fibroblast markers within a single tissue. Using this
approach, along with lineage tracing studies, we observed that a population of resident
dermal fibroblasts in normal skin, labeled with FSP1/S100A4, acquire the
myofibroblast phenotype associated with acquisition of ⍺SMA expression. Importantly,
not all ⍺SMA+ cells arose from FSP1/S100A4+ progenitors, indicating that there exist
at least two populations of fibroblasts which contribute to the pool of activated
myofibroblasts during tissue repair.
Further experimentation was carried using transgenic mouse models which
allow selective depletion based on expression of fibroblast markers such as ⍺SMA,
FSP1/S100A4, FAP, and Collagen1⍺1. Using these models, we were able to identify
unique phenotypes associated with depletion of these populations in the context of
wound repair. While depletion of ⍺SMA+ cells resulted in a complete inability to reepithelialize, results from other depletion models were more nuanced, affecting
collagen deposition, revascularization, and dermal thickness.
The work presented here offers novel insights on the dynamic nature of wound
healing fibroblasts and proposes new avenues for the treatment of chronic wounds.
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Chapter 1. Introduction
1.A. Dermal wound and repair process
Over 6 million people in the United States alone suffer from chronic wounds,
with estimated annual treatment costs reaching $25 billion (1-3). Chronic wounds may
ensue due to continuous injurious stimuli, and/or result from impairment in the normal
wound repair process. Impaired wound healing negatively impacts the affected tissue,
and can lead to excessive scarring, dehiscence, chronic ulcers, and infection (4). By
definition, chronic wounds are wounds that fail to progress through the normal phases
of wound healing, either persisting longer than six weeks or recurring frequently (5).
Although there are many potential origins for non-healing wounds presented in the
clinic, most ulcers are caused by ischemia due to diabetes, venous stasis, or pressure
(6-8). Regardless of their varying etiology, chronic wounds share the common features
of a prolonged and exaggerated inflammatory response, persistent infection,
increased reactive oxygen species (ROS), and the inability of dermal and epidermal
cells to respond to reparative stimuli (9, 10). Dermal wounds, in particular chronic
dermal wounds, not only pose a significant economic burden, but severely reduce
quality of life and continue to present as a clinical challenge with a need for more
effective therapeutic approaches.
The clinical challenge of dermal wound healing, such as in malignancies as
well as in aesthetic reconstruction, motivated a growing body of research aimed to
gain better control over the responses involved in the wound healing process. A
burgeoning field in cosmetic and regenerative medicine has made use of cellular and

2

acellular grafts to aid the repair of damaged tissues in patients whose normal healing
response is impaired as well as in the treatment of acute wounds (11-14). Various
dermal substitutes have been developed for the reconstruction of human skin, but the
results in the clinic have remained elusive, resulting in issues such as scarring,
insufficient vascularization, host rejection, absence of adnexal structures in the skin,
lack of long term integration, and variable response rates (11, 13). A plausible
explanation proposed for the inconsistencies observed between the promising preclinical findings and the poor outcomes in patients lies in the crude nature of cell
extracts used for skin replacements. These biological skin substitutes often consist of
a mixture of a matrix proteins and either keratinocytes, fibroblasts, or both. Allogenic
cells are collected from cadaver or neonatal foreskin, expanded in culture, and
cryopreserved prior to the preparation of skin equivalents (12). However, these
approaches show limited success in the transplant of cells that participate in wound
repair and regeneration; and it underscores the need for a more precise cellular and
molecular knowledge of the functional components of dermal wound repair.
Dermal wounds result from the injury of the soft covering of animals or skin.
The skin is composed of two layers: the epidermis and the dermis (Figure 1). The
epidermis comprises the outermost layer of the skin, providing the protective barrier
against UV radiation, outside pathogens, excessive water loss, as well as physical
and chemical insults. This layer consists of a stratified squamous epithelium
composed primarily of keratinocytes, which act to produce protective keratins and
maintain the structural integrity of the skin in response to insults. The dermis is itself
composed of the papillary and reticular dermis, and this layer houses the hair follicles,
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Figure 1. Layers of the skin and constituent parts
The skin is composed of the epidermis and dermis. The dermis itself can be
further subdivided into the papillary dermis, reticular dermis, and an underlying
hypodermis composed of fat and connective tissue. Each of these
compartments contains specialized cells for their function and maintenance.
(Driskell RR and Watt FM, Understanding fibroblast heterogeneity in the skin,
Trends in Cell Biology 2015). Copyright Clearance 11699634
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sebaceous glands, and sweat glands.
The dermal wound healing process is described as the succession of three
phases, defined on the basis of specific histomorphological changes (Figure 2).
These phases

include 1) the inflammatory phase, 2) the proliferative phase

(development of granulation tissue), and 3) the regeneration phase (including
maturation and scar formation) (15). In humans, the final remodeling phase can span
years until the regenerated tissue resembles the uninjured skin, and even then, the
strength of the dermis and collagen buildup may remain impaired. Critically, the three
phases of dermal wound repair are largely arbitrary, with considerable overlap with
regards to functional changes and the cell populations involved (5). Within these
phases, hallmarks of dermal wound healing include the recruitment and accumulation
of immune and mesenchymal cells, remodeling of the extracellular matrix in the wound
bed, and an angiogenic response. These distinct components operate in a complex
and highly-coordinated network to ensure wound closure and repair.

1) The inflammatory phase
The initial disruption of dermal tissue is immediately followed by the formation
of a blood clot, reestablishing hemostasis and providing extracellular matrix for cell
migration (5). Minutes following injury, blood vessels are constricted to prevent blood
and fluid loss. Activated platelets aggregate at the sites of vessel injury, forming a
temporary seal that covers the fractured vessel wall. These aggregated platelets form
a fibrin clot and provide a matrix scaffold for neutrophils and monocytes. The platelets
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Figure 2. The three phases of wound repair
a. The inflammatory phase. In the first three days after injury neutrophils,
macrophages and lymphocytes are attracted to the wound site
b. The proliferation phase. Three to ten days after wounding new blood vessels
are formed, fibroblasts proliferate and lay down extracellular matrix
components, and keratinocytes begin to migrate along the injured dermis to
re-epithelialize the wound
c. The resolution phase. Begins in earnest after re-epithelialization is
completed. The cellular density of the granulation tissue is reduced and the
extracellular matrix is remodelled
(Schafer M and Werner S, Cancer as an overhealing wound: an old hypothesis
revisited, Nature Reviews Molecular Cell Biology) Copyright Clearance
11699635
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trapped in the clot function as a barrier not only to encourage hemostasis but also to
stimulate immune cell recruitment and activation to the wound. Platelets contain
specialized organelles referred to as alpha granules containing both clotting factors
and growth factors, including platelet-derived growth factor (PDGF), insulin-like
growth factor-1 (IGF-1), epidermal growth factor (EGF), and transforming growth
factor-beta (TGFβ). Together these factors function to attract and activate fibroblasts,
endothelial cells, and macrophages, initiating the wound healing cascade.
Granulocytes (or polymorphonuclear leukocytes, PMN) are possibly the first
immune cells, recruited by platelet-derived cytokines, to infiltrate the wound, adhering
to endothelial cells in the blood vessels adjacent to the wound. Once at the wound
site, these cells phagocytose bacteria and foreign particles, eliminating them via the
release of degrading enzymes and oxygen-derived free radicals. During normal
wound healing in mice, PMN accumulation is maximal two days following wounding,
and these cells gradually decrease in number via apoptosis or phagocytic clearance
prior to complete re-epithelialization (16). However, in the case of chronic wounds,
neutrophils remain abundant (17).
The initial PMN influx is followed by the migration of monocytes recruited from
the bone marrow and systemic circulation to the wound site, where they differentiate
locally into macrophages (18). This infiltration peaks two days following dermal wound,
and gradually decreases with time during the maturation phase. Macrophages release
additional cytokines and growth factors into the wound, facilitating the recruitment of
fibroblasts, keratinocytes, and endothelial cells. Macrophages are presumably
associated with the resolution of local inflammation, as well as setting up for the
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subsequent phases of wound healing, including angiogenesis, granulation tissue
formation,

fibroblast

recruitment

and

extracellular

matrix

remodeling

(19).

Macrophage-derived growth factors, such as PDGF and vascular endothelial growth
factor (VEGF), initiate granulation tissue formation.

2) The proliferative phase (development of granulation tissue)
The proliferative phase of wound healing involves neo-angiogenesis, the
proliferation of fibroblasts, and re-epithelialization of the wound site. During this phase,
the dead space resulting from injury is replaced by new tissue. This phase is often
referred to as the granulation stage of wound repair due to the formation of granulation
tissue, referring to the pink granular appearance of invading capillaries within the
wound. Granulation tissue is made up primarily of proliferating fibroblasts, capillaries,
and tissue macrophages within in a matrix of collagen and the glycoproteins
fibronectin and tenascin.
During this stage epithelial cells at the wound margins, and any surviving
dermal epithelial appendages within the wound bed, begin their proliferation and
migration beneath the hardened scab formed during the early inflammatory phase.
The epidermis adjacent to the wound edge begins to thicken and keratinocytes
weaken their attachment to the underlying dermis in order to facilitate their migration
towards the wound center. When the advancing epithelial cells meet, further
movement is halted by contact inhibition.
Within the wound bed, fibroblasts are attracted to the wound site by the
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signaling molecules, including PDGF and TGFβ. Fibroblasts are stimulated to
proliferate and produce a provisional matrix of fibronectin and hyaluron (HA). In the
granulation tissue, activated fibroblasts are in part defined by their acquired
expression of alpha-smooth muscle actin (⍺SMA), and often referred to as
myofibroblasts. The expression of ⍺SMA in microfilament bundles or stress fibers
endows myofibroblasts with contractile properties. The accumulation of ⍺SMA+
fibroblasts plays a major role in the contraction, formation, and maturation of the
granulation tissue (20). Fibroblasts, as detailed below, are however a complex
population of cells with likely distinct roles and functions in the maturation of the
granulation tissue (21). They presumably synthesize and deposit a stronger matrix of
collagen and proteoglycans that eventually replace the provisional matrix. This newly
constructed extracellular matrix (ECM) provides support for the expansion of other
cells within the wound.
Apart from fibroblasts accumulation and ECM remodeling, angiogenesis and
vasculogenesis form a vital component of the wound healing cascade. This process
not only results in the replacement of damaged or excised vessels, but also provides
a source of nutrients for the increased cell density in wounds during repair. Modulating
wound angiogenesis in itself has been consider as a potential therapeutic target, as
delayed or defective angiogenesis is implicated in healing impairment (22-25).

3) The resolution phase (including maturation and scar formation)
The final stage of wound repair is the resolution, or remodeling, phase. This
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step overlaps with the development of granulation tissue and may continue over a
period of years before the wound site again resembles its uninjured form. During this
phase the provisional matrix matures as fibronectin and HA are broken down, and
collagen bundles thicken (26). Type III collagen, a principal component of the
immature granulation tissue, is gradually replaced by type I collagen. Lastly, elastin,
which is responsible for skin elasticity, re-emerges. However, the repaired dermis
never regains the original strength or plasticity of normal, unwounded skin (27). In the
resolution phase of healing the cell number is dramatically reduced, presumably due
to apoptosis of myofibroblast and vascular cells (28). As the ECM is continually
remodeled, there is ongoing collagen synthesis and breakdown.

1. B. Fibroblast biology and functions
Fibroblasts are cells of mesenchymal origin and are present in many tissues in
the body. Despite, or perhaps due to, their pervasiveness within the body, a precise
definition of fibroblasts function has remained elusive (21, 29). Morphologically,
fibroblasts are defined as elongated cells exhibiting a spindle-like shape which adhere
to tissue culture substrates (30). Resident fibroblasts are normally in a quiescent state
and are primarily considered to be responsible for the establishment and maintenance
of connective tissue stroma. However, their functional definition has been further
expanded to describe cells capable of secreting both structural and non-structural
ECM

molecules,

reorganizing

and

remodeling

the

ECM

through

matrix

metalloproteinases, regulation of the inflammatory response, and participation in both
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autocrine and paracrine signaling with other cell types (29, 31).
In injured tissues, fibroblasts have been found to transition to an activated, or
myofibroblast, state and take part in many aspects of the tissue remodeling cascade
(32-35). Myofibroblasts were originally identified on the basis of ultrastructural
morphology. Myofibroblasts could be distinguished from normal, quiescent tissue,
fibroblasts on the basis of their prominent microfilament bundles and shared
characteristics with smooth muscle cells (36) (37). Morphologically, the myofibroblasts
contain contractile apparatus analogous to the stress fibers present in cultured
fibroblasts. Myofibroblasts have been identified in many pathological conditions
including keloid scars in the skin, renal fibrosis, fibrotic liver, and idiopathic pulmonary
fibrosis (38-42). Cells with features of myofibroblasts have also been described in
tumors, where they have been termed cancer-associated fibroblasts (43, 44).
The transition between normal fibroblast and myofibroblasts is considered to
be controlled primarily through TGFβ signaling. TGFβ is first produced by phagocytic
cells and subsequently by fibroblasts, initiating a self-perpetuating cycle leading to the
appearance of myofibroblasts. TGFβ is a well-studied growth factor that exerts many
biological actions during development and tissue repair (45-48). In fibroblasts, TGFβ
induces the expression of ⍺SMA and stimulates the production of collagen type I.
Despite their roles in wound healing, fibrosis, and cancer, a reliable definition
of activated fibroblasts remains elusive due to their heterogeneous nature (29, 44).
The filament protein alpha-smooth muscle actin (⍺SMA) is currently the predominant
cellular marker for myofibroblasts. However, other fibroblast-associated proteins such
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as intermediate filament associated proteins, transmembrane proteins, and ECM
molecules, have also been associated with fibroblasts involved in tissue repair (Table
1). Even with a growing list of cellular markers used to delineate fibroblasts, no
consensus marker or group of markers have been able to capture the entirety of
fibroblast populations (32, 49). This issue is further compounded by findings indicating
considerable, but not complete, overlap in the expression of putative fibroblast
markers (50, 51). The molecular marker-based definition of fibroblasts thus also
includes exclusion criteria, such as lack of expression of immune (e.g. CD45) or
endothelial markers (e.g. CD31) (further detailed below). The functional heterogeneity
of fibroblasts, in development and tissue repair/remodeling, remains an active area of
investigation (11, 21, 49, 52).

Table 1. Putative Fibroblast Markers
Fibroblast Marker

Function

Also Expressed In

Reference

α-Smooth Muscle Actin
(αSMA)
Vimentin

Intermediate-filament associated
protein
Intermediate-filament associated
protein
Intermediate-filament associated
protein

Pericytes, smooth muscle cells

(53)

Endothelial cells, neurons

(50)

Macrophages

(54)

Serine Protease

Activated melanocytes, macrophages

(55)

Collagen biosynthesis
Growth factor receptor

Osteoblasts
Mesenchymal stromal cells

(56)
(57)

Receptor tyrosine kinase

Smooth muscle cells, adipose tissue

(58)

Fibroblast Specific Protein
1(FSP1) / S100 CalciumBinding Protein A4 (S100A4)
Fibroblast Activation Protein
(FAP)-α
Collagen 1
Platelet Derived Growth Factor
α (PDGFRα)
Discoidin Domain Receptor 2
(DDR2)

1.C. Dermal wound fibroblasts in tissue repair
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Fibroblasts, a dominant cell type in dermal wound healing, are considered
functional contributors to the wound healing process. Long considered to primarily
function to establish and remodel the ECM, fibroblasts have now been demonstrated
to interact closely with a multitude of cell types including immune cells (59), endothelial
cells (23, 24), keratinocytes (60), and adipocytes (61-63). Additionally, dysregulation
of fibroblast proliferation and function has been associated with the two major types
of wound related ailments: excessive scarring/fibrosis and incomplete wound healing
(34). Therefore, studies of fibroblast functions and dysfunction during wound healing
would offer important new insights with potential advancements in wound
therapeutics.
The first wave of fibroblasts recruitment emerges together with the sprouting
vasculature in wound healing. In addition to their role in the production of basement
membrane proteins, fibroblasts engage in paracrine and autocrine interactions in the
skin (64-68). Fibroblasts release growth factors/cytokines that play a significant role
in wound repair through their signaling with keratinocytes to stimulate reepithelialization. Myofibroblasts disappear from the wound site, presumably via
apoptosis, following which a distinct fibroblast population accumulate to form a
collagenous matrix (69). However, impaired remodeling of the collagenous matrix
results in the formation of scar tissue (15, 70, 71). Persistence of myofibroblasts in a
closed wound is a characteristic of hypertrophic scars, often found in burn injuries (28,
53).
As described above, both positive selection (⍺SMA+, Col1a1+, FSP1+, etc) or
negative selection (CD31-, desmin-, CD45-) have been used to study fibroblasts in
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wound healing. Although a clearer distinction between fibroblasts in normal and
diseased tissues/organs (e.g. fibrosis and cancer (29, 44) is emerging; the cutaneous
fibroblasts in intact skin and the healing wound are both heterogeneous and diverse.
Studies have focused on distinguishing between fibroblasts from the papillary (upper)
and reticular (lower) dermis, which were shown to differ in their in vitro proliferation
rates, capacity for matrix generation, and production/response to cytokines (72-75).
These studies relied on the mechanical separation of the skin layers and ex vivo
expansion. However, this strategy lacks the capacity to recapitulate interactions with
other cell populations which occur in homeostatic tissues and during tissue
remodeling.

More

recently,

extensive

immunolabeling

and

lineage

tracing

experiments (57) have indicated that proliferative and matrix-synthesizing reticular
fibroblasts were most robustly captured by the transmembrane protein Dlk1, while the
papillary dermis fibroblasts were found to be Dpp4 positive. The growth factor receptor
PDGFR⍺ was found to be an early marker of both lineages (57). However, this study
focused on the acquisition of markers during the course of development, rather than
in the repair process.
Subpopulations of fibroblasts reside in distinct anatomical locations within the
skin. At least three subpopulations have been identified in the dermis: superficial (or
papillary) fibroblasts, reticular fibroblasts, and fibroblasts associated with hair follicles.
These cell subpopulations can be isolated and exhibit distinct phenotypic and gene
expression differences when cultured (72, 74, 76, 77). Dermal papilla fibroblasts have
been described in the dermal sheath that surrounds the outside of the hair follicle.
They are involved in the regeneration of the dermal papilla and can also become
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wound healing myofibroblasts after a lesion or injury (78-80). Fibrocytes, defined as
hematopoietic derived cells expressing leukocyte markers and capable of
synthesizing collagen. These cells may be recruited to the injured skin with
inflammatory cells during the early stages of wound repair and subsequently acquire
a myofibroblastic phenotype (81-83).
Papillary fibroblasts, as their name indicate, reside in the papillary dermis, a
~300-400um thin layer of poorly organized collagen fiber bundles, in contrast with the
thicker and well-organized fiber bundles of the reticular dermis (77). The depth of the
papillary dermis is variable depending upon age, anatomical location, and other
factors. The papillary dermis contains more type III collagen than the type I collagen
rich reticular dermis (84). The separation of the papillary and reticular layers of the
skin allows establishment of explant cultures of cells from each layer. Papillary
fibroblasts are more proliferative than reticular fibroblasts (72, 76, 77, 85, 86). When
seeded into layers of type I collagen, reticular fibroblasts produce greater contractions
than do papillary fibroblasts (85, 86). Studies have indicated that the initial phase of
cutaneous wound repair is mediated by the reticular fibroblasts (57). By contrast,
upper dermal fibroblasts are recruited during subsequent phases of wound repair,
during re-epithelialization and hair follicle formation.
Despite ongoing studies and recent advances (11, 21, 87), the functional
characterization of dermal fibroblast in wound repair has been hampered by an
inability to identify and target such a heterogenous cell population. In this thesis, novel
approaches were developed, which, coupled with powerful mouse genetic
engineering, enabled the capture of the dynamic changes in fibroblasts composition
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during cutaneous wound repair and functionally tease out their contribution to wound
closure. The novel immunolabeling techniques detailed therein, and the use of genetic
fate mapping for fibroblasts with genetically engineered mouse models (GEMMs),
allowed for the visualization of multiple markers during the wound repair process.
Further, additional GEMMs allowing for the targeted depletion of defined cell
populations during cutaneous wound repair offered novel insights into the functional
contribution of distinct fibroblasts subpopulations. Critically, our studies have
employed the most common in vivo model of wound healing, namely the full thickness
skin (FTS) dermal punch model. This model involves the surgical excision of the
epidermis and dermis to the depth of the fascial planes or subcutaneous fat (88). The
model follows the standard process of inflammatory, proliferative, and resolution
phases detailed above.
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Chapter 2. Heterogeneity of dermal wound fibroblasts
2. A. Fibroblast marker expression in dermal wound injury
To ascertain the fibroblast heterogeneity in dermal would repair, the full
thickness skin (FTS) dermal punch model was established. In this model, the
epidermis and dermis layers of the skin are excised surgically. Adult mice ranging from
8-12 weeks of age were wounded bilaterally on their dorsal side using a sterile dermal
8mm biopsy punch (Figure 3A). The wound repair process was evaluated, and
distinct time points were chosen to represent the various stages of the wound healing
process,

from

inflammation

(Day

3-6),

to

granulation

(Days

9-12),

and

remodeling/resolution (Days 14-32). Visual inspections of the wound diameter
enabled the measure of rate of wound closure (Figure 3B). Representative H&E
imaging of the wounds and normal skin allowed for further characterization of the
stages of wound repair, and the definition of wound margins and skin tissue layers for
subsequent immunohistochemical analyses (Figure 3C).
Initial characterization of the putative dermal fibroblasts markers, namely type
I collagen, ⍺SMA, FSP-1/S100A4 and Vimentin, revealed both compositional and
spatial distinctions during dermal wound healing (Figures 3-6). In normal skin, type I
Collagen is densely concentrated at the dermis (Figure 3D). At three days following
wounding, collagen staining was limited to the margins. By day 9, collagen positive
area was visible throughout the forming granulation tissue, but it was not until day 30
post-wounding that collagen density approached pre-wound levels. In contrast,
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immunostaining for ⍺SMA positive fibroblasts revealed low expression in normal skin,

A
Day 3

Day 9

Day 12

Day 30

B
1cm

D

Collagen 1

H&E

C

Figure 3. Overview of the full-thickness skin (FTS) wound healing process
(A) Schematic cartoon of wound generation and closure in the full thickness
wound model
(B) Representative macroscopic images of mouse wounds at days 3 through 30
post-wounding
(C) Representative histological sections of normal skin and wounds at days 3
through 30 post-wounding (H&E), black bars indicate wound region
(D) Representative immunohistological sections of normal and wounded skin
stained for Collagen 1
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isolated primarily to cells associated with blood vessels and hair follicles (Figure 4A).
At day 6 post wounding, ⍺SMA positive cells were most prevalent in the expanding
lower dermal regions at the margins of the wound site (Figure 4B). By day 9, ⍺SMA
positive cells were found at the innermost areas of the granulation tissue and showed
a precipitous fall in positive cell number following (Figures 4D). In contrast to ⍺SMA,
immunolabeling for FSP1/S100A4 was prevalent in normal skin, especially at the
interface between the dermis and epidermis (Figure 5A). At day 6, positive cells were
already visible throughout the developing granulation tissue (Figure 5B), but there did
not appear to be any increase in positive cell number at later time-points (Figures 5CD). Interestingly, Vimentin positive immunolabeling was low in both normal skin and
early wound timepoints, isolated primarily to blood vessels (Figures 6A and B).
Wound tissue at day 9 and 14 however, showed an increase in vimentin positive
staining (Figures 6C and D).
Further, transcriptomic analyses of the skin for the above listed makers as well
as Fibroblast Activation Protein (FAP, another fibroblast marker subject to further
study below) showed expression of FSP-1/S100A4 (S100A4), and to a lesser extent
Vimentin (Vim), rise and peak as early as day 3 post wounding, whereas ⍺SMA
(Acta2) and Fap expression rise and peak and day 6 post wounding (Figure 7).
Transcript levels of Col1a1 showed no specific upregulation throughout wound repair
(Figure 7). Collectively, these results indicate that the expression of the fibroblast
markers evaluated is dynamic during the wound repair process (time) and in their
pattern of expression (heterogeneous spatial distribution), and that transcript and
protein levels are distinctly coupled. These findings underscored the heterogeneity of
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⍺SMA
200um

A

Normal Skin

B

Day 6

C

Day 9

D

Day 14

Figure 4. ⍺SMA expression during cutaneous wound repair
Representative immunohistological sections of normal skin and wounds at days
6 through 14 post-wounding (⍺SMA). Wound margins are labeled with dashed
black lines
(A) Representative image of ⍺SMA immunolabeling in normal skin
(B) Representative image of ⍺SMA immunolabeling in Day 6 wounds
(C) Representative image of ⍺SMA immunolabeling in Day 9 wounds
(D) Representative image of ⍺SMA immunolabeling in Day 14 wounds
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FSP-1/S100A4
200um

A
Normal Skin

B

C

D

Day 6

Day 9

Day 14

Figure 5. FSP1/S100A4 expression during cutaneous wound repair
Representative immunohistological sections of normal skin and wounds at days 6
through 14 post-wounding (FSP-1). Dashed black bars indicate wound margins
(A) Representative image of FSP1/S100A4 immunolabeling in normal skin
(B) Representative image of FSP1/S100A4 immunolabeling in Day 6 wounds
(C) Representative image of FSP1/S100A4 immunolabeling in Day 9 wounds
(D) Representative image of FSP1/S100A4 immunolabeling in Day 14 wounds
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Vimentin
200um

A

Normal Skin

B
Day 6

C

Day 9

D
Day 14

Figure 6. Vimentin expression during cutaneous wound repair
Representative immunohistological sections of normal skin and wounds at
days 6 through 14 post-wounding (Vimentin). Dashed black lines indicate
wound margins.
(A) Representative image of Vimentin immunolabeling in normal skin
(B) Representative image of FSP1/S100A4 immunolabeling in Day 6 wounds
(C) Representative image of FSP1/S100A4 immunolabeling in Day 9 wounds
(D) Representative image of FSP1/S100A4 immunolabeling in Day 14
wounds
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Figure 7. Differential expression of genes associated with fibroblasts and fibroblast
activation during cutaneous wound repair
The fold change in Acta2 (⍺SMA), Fap, FSP-1, Vimentin, and Collagen1⍺1 gene
expression in wounded skin between days 3 and 32 post-wounding compared to
normal skin controls (n= 4 mice per group)
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fibroblasts in dermal wound repair and suggest distinct functional contribution to the
wound healing process.

2. B. Spatial distribution and dynamic changes in fibroblasts population in dermal
wound repair
In order to accurately quantify the dynamic expression of putative fibroblast
markers during wound healing, a multiplex immunolabeling protocol based on
tyramide signal amplification combined with multispectral imaging was developed.
Briefly, this process occurs through three sequential steps. First, as in
immunohistochemistry, sections from paraffin embedded tissues are probed with
HRP-labeled antibodies against the protein of interest. Next, the HRP catalyzes the
conversion of tyramide derivatives to activated fluorescent tyramide residues which
become covalently bound to the targeted protein. Antigen retrieval strips the tissue
section of the HRP-antibody but not the bound fluorescent residues (Figure 8A). The
method was proven useful to capture cell identity, in a tissue section, on the basis of
immunolabeling multiple markers (89). This approach offered a number of advantages
for the study of fibroblast heterogeneity in dermal wound repair. Unlike traditional
immunostaining methods, this procedure allows the visualization of up to eight
markers within a single slide without loss of spatial resolution, enabling the analysis
of yet additional markers while also enabling analyses of markers co-expression in
dermal fibroblasts and distinction from other, non-fibroblast, cell types (Figure 8B-C).
For example, endothelial cells that express the fibroblasts markers of interest (FSP-
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HRP catalyzes
conversion of
tryamide molecules
into reactive free
radicals

Activated tyramide
molecules bind near
antigen
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removes bound
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Figure 8. Schematic of multispectral imaging platform procedure
(A) Schematic cartoon of tyramide signal amplification procdure
(B) Representative images displaying the same section of tissue with each individual marker
after spectral un-mixing
(C) Composite false-color image generated from (B)
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1/S100A4, ⍺SMA or Vimentin), via acquisition of an endothelial to mesenchymal
(EndMT) program realized in tissue damage (90), can be excluded from subsequent
analysis based on their expression of CD31 (PECAM-1), a protein involved in
endothelial cell junctions (Figure 8B-C). Multispectral imaging and scanning of the
tissue section also permits the use of image analysis software and pattern recognition
algorithms. These refine the spatial distribution analyses as it enables tissue
segmentation based on morphological features and enables definition of distinct skin
layers, including dermis, epidermis, and muscle and adipose tissue layers (Figure 9AC). Finally, using cell segmentation algorithms, the signal intensity from each marker
can be ascertained on a per cell basis, enabling the precise measure of the number
of positive cells within the analyzed area rather than total and relative image
fluorescent intensity.
To investigate the contribution of cells expressing different fibroblast
markers to the wound healing process, a multiplex panel consisting of ⍺SMA, FSP1/S100A4, Vimentin, CD31, Ki67 and DAPI was established (Figure 8C). Nuclear
labeling (DAPI) was used for cell phenotyping and, together with Ki67, define
proliferating cells. CD31, as detailed above, was used as an endothelial cell exclusion
marker. Wound tissue was collected at time-points between 3 and 32 days postwounding, as well as healthy, unwounded skin as control tissue. Analysis was carried
out exclusively on cells identified as being part of the dermal layer of the skin. In the
normal skin, nearly no vimentin positive cells were detected (Figure 10A),
corroborating observations made using immunohistochemistry (Figure 6).

The

normal skin displayed approximately 14% ⍺SMA+ cells (out of all cells in the section),
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A

B

Epidermis
Dermis
Muscle
Adipose
Non-Tissue

C

Figure 9. Definition of tissue segmentation of cutaneous wounds to restrict analysis to defined
areas
(A) Representative image demonstrating the demarcation of wound margins (red lines) and
region used for analysis (red arrow)
(B) Representative image demonstrating tissue segmentation of skin regions into epidermis
(red), dermis (yellow), muscle (green), adipose tissue (blue), and non-tissue (cyan)
(C) Representative 200x images of segmented skin regions
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Figure 10. Dynamic changes in expression of putative fibroblast markers during cutaneous
wound repair. N=6 mice per group
(A) Percentage of ⍺SMA+, FSP-1+, and Vimentin+ cells within the normal dermis and wound
beds from day 3 through 32 post-wounding
(B) Relative proliferation of fibroblast populations
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and 24% FSP-1/S100A4+ and 0.1% Vimentin+ cells (Figure 10A). During wound
repair, these cell populations changed in frequencies and showed distinct frequencies
relative to one another. Although ⍺SMA, FSP-1/S100A4, and Vimentin are often
utilized interchangeably as markers of fibroblasts during tissue regeneration, each
displayed

unique

dynamics

(Figure

10A).

In

agreement

with

previous

immunohistochemical analyses (Figure 4) and our gene expression results (Figure
7), the percent ⍺SMA+ cells increased at Days 3 and 6 following wounding, and
steadily declined thereafter (Figure 10A). By Day 6 post wounding, ⍺SMA-positive
cells emerged as the dominant fibroblast population, making up roughly 75% of
fibroblast marker positive cells. This accumulation is coordinated with an increase in
the frequency of ⍺SMA+/Ki67+ cells (increasing from 14% in normal skin to 24% at
Day 3 following wounding, Figure 10A-B), suggesting that increased proliferation of
⍺SMA+ fibroblasts, at least in part, contributed to the increase in percent ⍺SMA+ cells
early in the wound repair (Day 3 post wounding). This increase in the percent ⍺SMA+
fibroblasts is also in line with the reported increase in TGFβ secreted by several cell
types at this time-point during wound repair (91, 92). TGFβ is a potent stimulator of
differentiation of quiescent fibroblasts to the “activated fibroblast” or myofibroblast
phenotype (46, 93). The decrease in the percent ⍺SMA+ fibroblasts at the conclusion
of re-epithelialization (Day 14-32 post wounding, Figure 10A) similarly coincides with
the decrease in the stimulatory TGFβ signaling (46). In contrast, the percent Vimentin+
cells showed a dramatic increase in number by day 12 post wounding, reaching 90%
of all fibroblast marker positive cells by Day 21 (Figure 10A). Interestingly, although
a peak in the proliferating Vimentin+ cells is noted at day 3 post wounding (Figure
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10B), the accumulation of these cells in the wound was only obvious at day 12,
suggesting that Vimentin+ cells accumulation may not result from increased
proliferation. Interestingly, although FSP-1/S100A4 is prominently detected in the
normal skin (Figure 10A), there was very little variation in the % FSP-1/S100A4+ cells
during wound healing, and despite a peak in the proliferating FSP-1/S100A4

+

cells

also noted at day 3 post wounding. Since the percent of FSP-1/S100A4+ Ki67+ cells
were the highest amongst the fibroblasts population studied (⍺SMA+ and Vimentin+
fibroblasts, respectively) (Figure 10B), these results suggest a rapid turnover of the
FSP-1/S100A4+ cells during wound repair. The overall frequency of fibroblast marker
positive cells that increased during wound healing were returned to baseline levels at
Day 32. The lack of fully restored ⍺SMA+ cell populations by Day 32 may reflect the
loss in overall fibroblast number which occurs after wound healing, without the
complete regeneration of endothelial cells (Figure 10A). While normal skin contained
roughly 10% CD31+ cells and increased to 15% at day 6 post wounding, the number
of CD31+ cells made up only 5% of total cells at day 21 and 2% at day 32.
We next examined the degree of overlap between expression of these
fibroblast markers on a per cell basis. A weakness in traditional immunostaining
methods has been the difficulty in evaluating heterogeneity of marker expression
without loss of spatial information, limiting analysis to only two or three markers
simultaneously. Using a newly developed analysis platform, the marker phenotype
was determined and a truth table was generated in order to identify the degree of
overlap between marker positive populations. In normal and fully healed skin (Figure
11), the cells of the dermis were primarily made up of ⍺SMA+ and FSP-1/S100A4+
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cells, with between 5-15% of cells expressing both markers. However, by Day 6 post
wounding, when the number of ⍺SMA+ cells had increased to 45% of all cells in the
dermis, the majority population was ⍺SMA single expressing cells with the bulk of
FSP-1/S100A4+ cells also expressing ⍺SMA (Figure 11). Interestingly, by Day 14 post
wounding, when wound re-epithelialization is complete, not only did the frequency of
cells singly positive for Vimentin increased, but up to 23% of Vimentin+ cells also
expressed ⍺SMA (Figure 11). By Day 32 post wounding, 18 days following reepithelialization, the wound tissue had largely normalized and the relative overall of
fibroblasts marker expression was similar to that of normal skin (Figure 11). These
results indicate a dynamic overlap of fibroblasts marker expression during dermal
wound repair, and the changes in the shared fibroblast marker expression over time
raise the possibility of a common fibroblast progenitor cell giving rise to fibroblasts that
subsequently narrow their fibroblast marker expression. Alternatively, the overlap in
fibroblast marker expression, although unlikely, may simply reflect a promiscuous
expression pattern that challenge a functional resolution of fibroblast functional
heterogeneity. Subsequent functional studies below and in Chapter 3 however support
the former hypothesis.
To define if the overlap in fibroblast marker expression reflects a possible
differentiation of ⍺SMA+ fibroblasts at Day 3 post wounding from a putative FSP1/S100A4+ progenitor population found in the normal skin (Figure 10), we utilized
genetically engineered mice that enabled the lineage tracing of FSP-1/S100A4
expressing cells. The FSP-1/S100A4-Cre mice were bred to mT/mG indicator mice.
In these mice, all cells constitutively express a tdTomato transgene that converts to
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Figure 11. Co-expression of markers during wound repair
Venn diagrams showing extent of co-expression between cells expressing FSP-1 (blue), ⍺SMA
(red), and Vimentin (green) in normal dermis and wound beds from days 6, 14, and 32 postwounding, n=5 mice per group..
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green fluorescent protein (GFP) expression following expression Cre recombinase,
which in this model is under the control the FSP1-promoter. These mice were
wounded as described above and wound tissue was collected at Day 6 post wounding,
as this was the time-point with the greatest overlap in FSP1/S100A4 and ⍺SMA
expression. Immunolabeling of these tissues for ⍺SMA allowed quantitative analysis
of the degree to which ⍺SMA+ cells are derived from FSP1/S100A4+ progenitors. In
normal skin areas, FSP1/S100A4 lineage positive cells were localized to the epidermis
and hair follicles (Figure 12A) with minimal ⍺SMA+ cells present. Interestingly, within
the granulation tissue 38% of all ⍺SMA+ cells were found to be GFP+ (Figure 12B-C).
These results suggest that although some ⍺SMA+ cells arise from FSP1/S100A4+
progenitors, there exists a distinct population of ⍺SMA+ cells that do not (Figure 12C).
As indicated above, another advantage to the multiplex imaging lies in its
unique capacity to inform on spatial distribution. An understudied area of questioning
in the field of dermal wound healing has been the degree to which position within a
wound may influence the proliferation and abundance of fibroblast populations during
the wound healing process. Despite a position in the field that fibroblast proliferation
occurs at the wound margins, it remains unclear whether cells within the wound center
are phenotypically distinct from those at the edge of the wound. In order to determine
whether changes in fibroblast composition may be related to their position within the
healing wound, each fibroblast population was ‘binned’ based on distance from the
wound center (Figure 13A). Five ‘bins’ or areas were arbitrarily defined between the
center of the wound and its edge. Two such spatial fragmentations of the wound,
mirroring one another, could be defined from the center of the wound and either its
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Figure 12 Lineage tracing of FSP1/S100A4+ cells immunolabeled
with ⍺SMA
(A) FSP-Cre mTmG mice immunolabeled with ⍺SMA in normal skin
presented a clear distinction between FSP1/S100A4-lineage+
cells and ⍺SMA+ cells
(B) FSP-Cre mTmG day 6 wounds immunolabeled with ⍺SMA
(C) Quantification of the degree of FSP-Lineage positive and
negative cells in day 6 wounds which express ⍺SMA (n=4
wounds)
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Figure 13. Spatial distribution of fibroblast subpopulations in cutaneous wounds
(A) Left: Subdivision of wounds based on distance from wound edge with 0%
indicating wound edge and 100% indicating wound center. Examples of histogram
distribution for cells equally dispersed within the wound area (center) or showing
biased distribution (right)
(B) Distribution of FSP-1+ (left), ⍺SMA+ (center), and Vimentin+ (right) cells within the
wound at days 3 through 14 post-wounding. n=4 mice per group.
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left or right edge (Figure 13A). The mirrored bins were then combined for subsequent
analyses.

Two scenarios were drawn based on a predicted equal or biased

distribution of the fibroblasts population in the wound (Figure 13A). The results
showed that ⍺SMA+ cells appear to be present primarily at the leading edge of wounds
at each time-point during the wound healing process (Figure 13B). In contrast, FSP1/S100A4+ cells were generally found in the areas ahead of the leading edge.
Interestingly, despite the noted increase in vimentin+ cells during wound healing, the
cells appear equally distributed in the wound bed. These distinct patterns of fibroblasts
distribution in the wound bed during wound healing suggest distinct functions for these
cells in dermal wound repair.
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Chapter 3. Functional role of fibroblasts in dermal wound healing
3.A. Genetic approach to deplete fibroblasts population in dermal wound injury repair
To define the rate-limiting, functional contribution of distinct fibroblast
populations in dermal wound repair, we utilized an established conditional suicide
gene system in mice to deplete genetically-tagged cells (41, 94-96). Specifically, mice
were engineered to express the HSV-TK transgene under the control of a defined
gene promoter element (Figure 14). In our studies, we employed gene promoter
elements for the defined fibroblasts gene products detailed in Chapter 1 and 2. This
approach allows for the selective depletion of defined fibroblast populations.
Expression of the selected fibroblast promoter element in turn drives the expression
of viral thymidine kinase (TK). This does not impact the endogenous fibroblast gene
expression and has no impact on the mice viability (41, 94, 95). Notably, we
engineered mice with truncated or full-length TK transgene, the latter yielding male
infertility due to leaky TK expression in testes (97-99). Both forms of the transgenes
however show efficient conditional suicide gene expression and cell targeting (vide
infra).
In cells expressing the TK transgene, administration of Ganciclovir (GCV, a
synthetic analog of 2′-deoxy-guanosine) results in conversion of the prodrug to
ganciclovir triphosphate, a competitive inhibitor of dGTP incorporation into DNA,
leading to cell cycle arrest and cell death (100). This approach, in contrast with
systemic gene knockout mice, antibody depletion, or ectopic treatments, uniquely
enables the dynamic functional characterization of proliferating fibroblasts that
accumulate during dermal wound repair. The efficacy of the distinct constructs

37

Exon1

Fibroblast Promoter
2.5-5.0 kbp
viral
thymidine
kinase

GCV

GCV
monophosphate

HSV1TK
1.1kbp

cellular
kinase

Inhibition of
DNA synthesis

SV40p(A)
0.2 kbp

Cell cycle
arrest/Apoptosis

Figure 14. Schematic of thymidine-kinase mediated cell depletion in transgenic mice
Top: Construct map of transgenes injected into C57 zygotes for the production of
transgenic mice
Bottom: Mechanism of thymidine kinase mediated cell ablation. Thymidine kinase
converts ganciclovir (GCV) into a nucleotide analog which becomes incorporated into
DNA during replication, causing chain termination and inability to proliferate
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generated was tested using primary cultures of mouse ear fibroblasts. Mouse ear
fibroblasts, from TK+ and TK- mice, were expanded in vitro. After collagenase
dissociation and a culture period of no more than two weeks, ear fibroblasts were
seeded to 96 well plates at 1x104 cells per well and treated with GCV at
concentrations of 0, 5, and 50uM. After a treatment period of three days, cell viability
was measured using trypan blue exclusion. Previously studies reported on the efficacy
of the ⍺SMA-TK and FSP1 -TK transgenes using a similar procedure (41, 95). The
results from these experiments indicated a specific, dose-dependent reduction of in
cell viability for Col1a1-TK and FAP-TK expressing cells in comparison to wild-type
(WT) control cells (Figure 15A-B). The reduction in Col1a1 expressing ear fibroblasts,
evaluated by immunolabeling, was also evident in cultures of cells from Col1a1-TK
mice subjected to GCV, when compared to untreated Col1a1-TK expressing ear
fibroblasts (Figure 15C). Interestingly, the in vitro targeting of Col1a1 expressing ear
fibroblasts also resulted in a decrease in ⍺SMA expressing fibroblasts (Figure 15C).
Phenotypic characterization of wound closure rate and evaluation of fibroblast
depletion using the conditional suicide gene construct was evaluated using FTS in
⍺SMA-TK (Figure 16), FSP1-TK (Figure 17), FAP-TK (Figure 18), Col1a1-TK
(Figure 19), and DDR2-TK (Figure 20) transgenic mice. These transgenes represent
the complex fibroblast heterogeneity observed during dermal wound repair (Table 1,
Chapter 2). On the day of wounding (Post Wounding Day 0), mice were treated with
GCV daily and wound area was measured until the day of wound closure in TK- (WT)
mice. Depletion of targeted cell populations were confirmed by immunohistochemistry
or in situ RNA hybridization. Targeted depletion of ⍺SMA+ fibroblasts resulted in a
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Figure 15. In vitro confirmation of cellular ablation of ear fibroblasts in generated
mouse models
(A and B) In vitro ganciclovir treatment of ear fibroblasts from Col1a1-TK or FAP-TK
mice demonstrates a dose-dependent ablation of viable cells compared to wild-type
littermates (WT). n=3
(C) Cultured ear fibroblasts without GCV treatment (left) or with GCV treatment
(right) immunostained with Collagen 1 (top) or ⍺SMA (bottom)
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defined interruption in the wound closure process, starting at roughly six days postwounding (Figure 16A). Whereas control (WT) mice showed complete wound closure
(0% wound area) at day 17 following wounding, ⍺SMA-TK mice present with an open
wound (32% wound area), showing a stalling in wound closure starting at day 6 of
wound repair (Figure 16A). Immunostaining for ⍺SMA in the wound bed, specifically
focusing on the dermis, indicated a significant reduction in ⍺SMA+ fibroblasts
(approximately 75% reduction, Figure 16B-C) when comparing WT mice at day 6 post
wounding (36% wound area) and ⍺SMA-TK mice at day 17 (32% wound area).
Targeted depletion of FSP-1/S100A4+ fibroblasts did not result in a significant
decrease in wound closure rate, with both FSP1-TK and WT mice showing complete
wound closure at day 17 following wounding (Figure 17A). Immunostaining for FSP1/S100A4 within the dermal layer of the wounds (Figure 17B) showed a significant
decrease in the FSP-1/S100A4+ cell population of approximately 25% (Figure 17C).
Targeted depletion of FAP+ fibroblasts resulted in a significant decrease in
wound closure rate presenting at Day 10 post wounding (Figure 18A). While WT mice
reached complete wound closure by Day 14 post wounding, FAP-TK mice presented
an open wound (12% wound area) up to day 16 (Figure 18A). Immunostaining for
FAP within the wound bed (Figure 18B) showed a significant decrease in the number
of FAP+ cells (approximately 35% less than WT mice, Figure 18C).
Targeted depletion of Col1a1+ fibroblasts in wounded mice presented with a
significantly impaired wound closure rate starting at Day 8 post wounding (Figure
19A). At Day 14 following wounding, when WT mice had reached full wound closure,
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Figure 16. Functional contribution of ⍺SMA+ fibroblasts in cutaneous wound closure
(A) Wound measurements following wounding in ⍺SMA-TK at Day 17 and wild-type mice at
Day 6 post wound induction
(B) Representative histological staining of ⍺SMA+ cells within the wound area
(C) Quantification of aSMA+ cell number in WT and ⍺SMA-TK wounds on Day 6 based on
immunohistological staining
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Figure 17. Functional contribution of FSP1/S100A4+ fibroblasts in cutaneous wound closure
(A) Wound measurements following wounding in FSP1-TK and wild-type mice
(B) Representative histological staining of FSP1+ cells within the wound area comparing
wounds from WT and FSP-TK mice at Day 17
(C) Quantification of FSP1/S100A4+ cell number in day 17 wounds from WT and FSP1-TK
mice based on immunohistological staining

43

A

C

0

2

4

6

8

10

12

14

120

Positive cells/40x field

***

***

***

50

***

Wound area (%)

FAP-TK

0

***

WT

100

100
80
60
40

16

WT

FAP-TK

Days Post Wounding

B

WT

TK

Figure 18. Functional contribution of FAP+ fibroblasts in cutaneous wound closure
(A) Wound measurements following wounding in FAP-TK and wild-type mice
(B) Representative histological staining of FAP+ cells within the wound area at day 17 post
wounding
(C) Quantification of FAP+ cell number in day 17 wounds from WT and FAP-TK mice based on
immunohistological staining

44

Col1a1-TK still presented with open wounds (7% of initial wound area, Figure 19A).
In situ RNA hybridization for expression of the Collagen1a1 gene suggested a
decrease in collagen production (Figure 19B-C).
Targeted depletion of DDR2+ fibroblasts did not result in a change in wound
closure rate, with both DDR2-TK and WT mice reaching full wound closure at Day 14
post wounding (Figure 20A). Immunostaining for DDR2+ cells within the repairing
dermis did not indicate any decrease in DDR2-TK mice (Figure 20B-C). As a control
for our staining procedure, heart and subdermal muscle sections were additionally
stained (Figure 20D) as these organs have been demonstrated to express high levels
of DDR2 (101).
Collectively, these results showcased a rate limiting functions for proliferating
⍺SMA+, Col1a1+ and FAP+ fibroblasts in dermal wound closure, in contrast with
proliferating FSP-1/S100A4+ fibroblasts. Despite a 25% depletion in FSP-1/S100A4+
fibroblasts, no impact was noted on wound closure. The lack of phenotypic changes
in DDR2-tk mice, compared to WT control, is explained by the scarcity of the DDR2+
fibroblasts; these mice effectively controlling for any potential GCV side effects. GCV
side effects were not observed.

3.B. Distinct roles of fibroblasts subpopulations in dermal wound closure
In addition to an inability to re-epithelialize, delayed or incomplete wound
repair often presents with two major deficiencies: 1) An inability to replace the lost
basement membrane at the wound site through production of collagen, and 2) A
decreased capacity to perform neo-angiogenesis to supply oxygen and nutrients to
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Figure 19. Functional contribution of Col1⍺1+ fibroblasts in cutaneous wound closure
(A) Wound measurements following wounding in Col1a1-TK and wild-type mice
(B) Representative histological in situ staining of Col1a1+ cells within the wound area
(C) Quantification of Collagen1a1+ stained area in WT and Col1a1-TK mice based on in situ
hybridization
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Figure 20. Functional contribution of DDR2+ fibroblasts in cutaneous wound closure
(A) Wound measurements following wounding in DDR2-TK and wild-type mice
(B) Representative histological staining of DDR2+ cells within the wound area at
day 14
(C) Quantification of DDR2+ cell number in Day 14 wounds based on
immunohistological staining
(D) Representative histological staining of DDR2+ cells in heart and subdermal
muscle sections
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the new tissue. These characteristics of the wound repair process were evaluated in
each transgenic system described above (Figures 16 to 20). As anticipated with the
observed impairment in closure rate (Figure 16), depletion of proliferating ⍺SMA+ cells
was associated with an inability to establish a granulation area or epithelial barrier
(Figure 21B, F). Depletion of proliferating FAP+ (Figure 21C) or Col1a1+ (Figure 21D)
fibroblasts also impaired granulation thickness (Figure 21F), whereas depletion of
FSP-1/S100A4+ fibroblasts did not significantly impair granulation thickness (Figure
21E-F) compared to WT controls. Although wounds from ⍺SMA-TK and Col1a1-TK
mice, compared to control mice, showed a predictably lower type 1 collagen
deposition, a marked increase in type I collagen was observed in FAP+ fibroblasts
depleted wounds, and no changes were observed in FSP-1/S100A4+ fibroblasts
depleted wounds (Figure 22).
A feature of a properly healed wound is the formation of new blood vessels via
neo-angiogenesis, allowing effective tissue perfusion of oxygen, metabolites and
cytokines. In alignment with the wound vessel density, a marked increase in wound
tissue hypoxia was noted in ⍺SMA+ fibroblasts depleted wounds compared to control
wounds (Figure 23B and 24B), and depletion of FSP-1/S100A4+ fibroblasts had no
impact on tissue hypoxia (Figure 23E and 24E). In contrast, whereas depletion of
FAP+ resulted in a mild decrease in CD31+ vasculature in the wound bed (Figure
23C), this did not translate in measurable increase in tissue hypoxia (Figure 24C). In
Col1a1+ fibroblasts depleted wounds, though CD31+ vessel density is markedly higher
when compared to control wounds (Figure 23D), tissue hypoxia was elevated (Figure
24D).
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Figure 21. Col1⍺1+ fibroblasts contribute to granulation tissue thickness in
cutaneous wound healing
(A-E) H&E staining of wound sections from (A) wildtype, (B) ⍺SMA-TK, (C) FAPTK, (D) Col1⍺1-TK, and (E) FSP1-TK mice at day of full wound closure in
wild-type mice. Black bars demarcate granulation tissue area.
(F)
Quantification of granulation tissue area in transgenic mice from (B-E),
compared to wild-type controls from the same experiment. n=4 per group
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Figure 22. Differential expression of collagen-1 in wounds with distinct depletion of
fibroblast subpopulations
(A-E) Collagen-1 staining of wound sections from (A) wildtype, (B) ⍺SMA-TK, (C)
FAP-TK, (D) Col1⍺1-TK, and (E) FSP1-TK mice at day of full wound
closure in wild-type mice.
(F)
Quantification of Collagen positive area in transgenic mice from (B-E),
compared to wild-type controls from the same experiment.
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Figure 23. Differential angiogenic response in wounds with distinct depletion of
fibroblast subpopulations
(A-E) CD31 staining of wound sections from (A) wildtype, (B) ⍺SMA-TK, (C) FAPTK, (D) Col1⍺1-TK, and (E) FSP1-TK mice at day of full wound closure in
wild-type mice.
(F)
Quantification of CD31 positive area in transgenic mice from (B-E),
compared to wild-type controls from the same experiment.
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Figure 24. Depletion of ⍺SMA+ fibroblasts promotes an hypoxic wound
microenvironment
(A-E) Hypoxyprobe staining of wound sections from (A) wildtype, (B) ⍺SMA-TK, (C)
FAP-TK, (D) Col1⍺1-TK, and (E) FSP1-TK mice at day of full wound
closure in wild-type mice.
(F)
Quantification of hypoxic area in transgenic mice from (B-E), compared to
wild-type controls from the same experiment.
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Taken together, these functional depletion studies highlighted a heterogeneous
response of distinctly captured fibroblast populations during dermal wound repair
(Table 2). Our results indicate that ⍺SMA+ fibroblasts play a critical role in completion
of wound closure by enabling repair of the granulation tissue, ECM remodeling and
angiogenesis (Table 2). While both FAP+ and FSP-1/S100A4+ fibroblasts exert
functions in wound closure, albeit to a lesser extent than ⍺SMA+ fibroblasts, their
impact on type I collagen deposition and angiogenesis was opposite (Table 2).
Interestingly, a seemingly contradictory phenotype is noted in Col1a1+ fibroblasts
depleted wound, wherein increased vessel density was associated with increased
tissue hypoxia. This raises the intriguing possibility that Col1a1+ fibroblasts regulate
the maturation of patent blood vessels during cutaneous wound repair. Finally, our
findings indicate that proliferating FSP1+ cells minimally act in the process of wound
repair (Table 2, Figure 17).
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Wound
Closure

Granulation
Tissue
Thickness

Collagen
-1

Angiogenesis
(CD31)

Hypoxia
(Hypoxyprobe)

↓↓↓

X

↓

↓

↑

FAP-TK

↓

↓

↑

↓

-

Col1⍺1-TK

↓

↓

↓

↑

↑

FSP1-TK

↓

-

-

-

-

⍺SMA-TK

Table 2. Summary of findings on the functional contribution of distinct fibroblast subpopulations in
cutaneous wound healing.
↑ Indicates increased closure rate, tissue thickness, or protein expression compared to control
mice
↓ Indicates decreased closure rate, tissue thickness, or protein expression compared to control
mice
- Indicates no change compared to control mice
X Indicates the inability to establish granulation tissue in ⍺SMA-TK mice
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Chapter 4. Origin and role of ⍺SMA+ fibroblasts in dermal wound repair
4.A. Dermal ⍺SMA+ fibroblasts control wound closure
The depletion of ⍺SMA+ fibroblasts during wound healing resulted in a
significantly impaired wound closure phenotype (Figure 16). This inability to complete
wound healing was evidenced by both a decreased closure and decreased reepithelialization (Figures 25 and 26). Because the formation of the hardened scab
can sometimes obscure measurement of wound closure, we next performed H&E
assessment of the migrating epithelial tongues at select time-points during wound
healing of both WT and ⍺SMA+ fibroblast depleted mice (Figure 26). While there was
no measured difference in re-epithelialization at Day 3 or 6 post-wounding, wounds
from ⍺SMA-TK began to show a lower degree of re-epithelialization at Day 12 (Figure
26). By Day 17 post wound induction, wounds in WT mice had completely reepithelialized. In contrast, wounds in ⍺SMA+ fibroblast depleted mice had regressed,
increasing from a mean epithelial tongue distance of 1.5mm at Day 12 to
approximately 3mm by Day 17 (Figure 26B).
Informed by the decreased collagen deposition (Figure 21B) and reepithelialization (Figure 26B) observed in wounds from ⍺SMA-TK mice, we next
investigated the nano-mechanical properties of the wound tissue (Figure 27). We
utilized atomic force microscopy (AFM), a mechanical process based on the
interaction of a very small flexible probe with the sample surface to determine the
compressive stiffness at the nanometer range. Regions throughout the repairing
dermis were selected for measurement of surface stiffness (Figure 27A) and 257
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Figure 25. Depletion of ⍺SMA+ fibroblasts prevents wound closure
(A) Top: Wound area measurements following wounding (day 0) in ⍺SMA-TK and wild-type
mice
Bottom: ⍺SMA staining of wounds at Day 6 post wounding
(B) Gross view of wounds in control and ⍺SMA-TK mice treated with GCV at days 0, 4, 8, and
16 post-wounding
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Figure 26. Impaired re-epithelialization in ⍺SMA+ fibroblasts-depleted wounds
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measurements were performed at each position. ⍺SMA+ fibroblast depleted wounds
exhibited a significantly decreased wound stiffness compared to WT mice (12.27kPa
in ⍺SMA-TK wounds compared to 13.57 kPa in WT wounds, Figure 27D)
Given the inability of ⍺SMA+ fibroblast depleted wounds to close by Day 17
(Figure 16), we performed experiments extending treatment in order to determine
whether the populations of ⍺SMA-negative fibroblasts may eventually compensate for
this loss (Figure 28). Interestingly, prolonged treatment of ⍺SMA-TK mice with GCV
completely prevented wound closure up to Day 32 (Figure 28B), at which point mice
were sacrificed due to body weight loss and moribundancy. ⍺SMA+ cell depleted
wounds increased in size as treatment continued, growing from approximately 27% of
initial wound area at Day 16 to 43% on Day 32 (Figure 28B). These results indicate
that the loss of ⍺SMA-positive cells cannot be compensated for by other cells.
Conversely when GCV treatment was stopped at Day 14, wounds were eventually
able to close, though complete closure did not occur until Day 42 post wounding
(Figure 28C).

4.B. Resident ⍺SMA+ fibroblasts functionally repair dermal wounds
Because transgene expression does not always correlate with the cells
identified through immunostaining, we first confirmed that cells targeted in our ⍺SMATK model follow a similar pattern to what was identified via our TSA panel. Due to the
difficulty in staining for the TK protein directly, we instead utilized ⍺SMA-RFP mice,
which express the fluorescent protein RFP under the same ⍺SMA promoter as our TK
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Figure 27. Reduced stiffness in ⍺SMA+ fibroblasts-depleted wounds
Wound sections from wild-type (top) and ⍺SMA-TK (bottom) mice were used for atomic force
microscopy (AFM) measurements (n=3 per group, 4 positions per wound, 257 measurements
per position).
(A) Optical microscopy images of tissue sections used for AFM, arrows indicate positions
within the wound tissue used for analysis
(B) Representative AFM height images. Each image shows a 10.0 x 10.0 μm field.
(C) Representative elasticity maps. The color map indicates the modulus of elasticity (in kPa)
evaluated using force curves generated at each point in the field. Each image shows a 50 x
50 μm field. This measurement does not give the absolute height but rather the height
relative to the lowest contact point in the field.
(D) Young’s elastic modulus distribution of section samples. Values were assembled in a
histogram and the median was calculated.
(E) Plot of individual measurements of Young’s elastic modulus collected from three normal
skin, day 17 WT wound, and day 17 ⍺SMA-TK wounds
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Figure 28. The impact of ⍺SMA+ fibroblasts depletion on wound closure is reversible
(A) Cartoon schematic of treatment arms.
(B) Wound closure in wild-type (blue) and ⍺SMA-TK (red) mice treated with GCV
daily for 32 days.
(C) Wound closure in wild-type and ⍺SMA-TK mice treated with GCV up to day 14.
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system. These mice have been previously developed in our laboratory and have been
demonstrated to show defined localization to cells identified by immunostaining in
other organs (41). ⍺SMA-RFP mice were wounded and wound tissues were harvested
at Day 3, 6, 9, and 14 for analysis of RFP+ cell abundance by microscopy (Figure
29A) and flow cytometry (Figure 29B). As observed in our previous experiments
(Figure 10A), uninjured skin showed a low degree of ⍺SMA positive cells (Figure
29C). By Day 6 post wounding there was an accumulation of ⍺SMA positive cells to
approximately 11% of total cells, followed by a decrease to 7% on Day 14 as the
wounds resolved (Figure 29C). Although these results are lower than what was
observed in our immunolabeling experiments (Figure 10A), the use of flow cytometry
does not allow us to limit analysis exclusively to the repairing dermis as we had
previously.
We next sought to determine the relative contribution of resident fibroblasts
compared to bone marrow derived mesenchymal cells to the pool of ⍺SMA+
fibroblasts during wound repair. We first investigated the co-localization of ⍺SMA with
the lower-lineage dermal marker Sca-1 (Figure 30). The use of Sca-1 positivity to
identify resident fibroblast lineages has been performed in several models (57, 102,
103). Immunolabeling for Sca-1 and examination of co-localization using flow
cytometry (Figure 30A) and microscopy (Figure 30B) demonstrated the presence of
⍺SMA+Sca-1+ cells within the Day 6 wound tissue.
We next performed bone marrow transplantation studies utilizing ⍺SMARFP mice and WT mice (Figure 31). We confirmed high bone marrow chimerism in
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Figure 29. Visualization of ⍺SMA-RFP+ fibroblasts in cutaneous wounds
Mice expressing RFP under the ⍺SMA promoter were wounded and tissues were
collected for analysis of RFP+ cells in normal skin and wounds from days 3, 6, 9, and
14
(A) Assessment of ⍺SMA+ fibroblasts (red) with Topro3 nuclear counterstain (blue) in
normal and wounded skin from ⍺SMA-RFP transgenic mice
(B) Flow cytometry analysis of RFP+ cells (gated population) in normal and wounded
skin
(C) Quantification of ⍺SMA-RFP+ cells in normal skin and 3, 6, 9, and 14 days post
wound induction
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Figure 30. ⍺SMA+ cells in the cutaneous wound co-express lower dermal
lineage marker Sca1
Normal skin and wound tissue was collected from ⍺SMA-RFP mice at six days
post wounding
(A) Flow cytometry analysis of wounds at day 0 (left) or day 6 (right). Cells
were stained with Sca-1 and co-expression with ⍺SMA+ cells was
evaluated based on gated regions
(B) Immunoflourescence staining of ⍺SMA-RFP normal skin and day 6
wounds with Sca-1 (green) and DAPI nuclear counterstain (blue)
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Figure 31. ⍺SMA+ fibroblasts accumulating in the cutaneous wound are not recruited from the
bone marrow.
Irradiated wild-type mice were transplanted with ⍺SMA-RFP bone marrow (or vice versa) and
FTS wounding was performed. Wounds were collected at six days post wounding and
abundance of ⍺SMA-RFP cells was measured
(A) Schematic cartoon of bone marrow transplantation experiments.
(B) Represntative fluorescence in situ hybridization (FISH) for Y-chromosome in bone
marrow transplantation of sex mismatched mice
(C) Flow cytometry for RFP+ cells (gated population) in transplanted mice. Wounded ⍺SMARFP mice without bone marrow transplantation (left) are provided for comparison
(D) Assessment of ⍺SMA+ fibroblasts (red) with DAPI nuclear counterstain (blue) in day 6
wound tissue from bone marrow transplanted mice
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sex-mismatched transplants (Figure 31B). Wild type mice were transplanted with
2x106 bone marrow cells from ⍺SMA-RFP donor mice, as well as the reverse, followed
by wounding. Mice were sacrificed at Day 6 post wounding and wound tissue was
evaluated for the presence of bone marrow derived ⍺SMA-RFP+ cells. Bone marrow
transplantation from ⍺SMA-RFP transgenic donors to wild type recipients
demonstrated that 0.75% of cells within a Day 6 wound were derived from the bone
marrow (Figure 31C). In contrast, ⍺SMA-RFP mice tend to show approximately 16%
RFP+ cells at the same time-point.
To determine whether these small numbers of bone marrow-derived ⍺SMApositive cells nonetheless play a crucial role in the repair process, sub-lethally
irradiated wild type mice were transplanted with bone marrow from ⍺SMA-TK mice
(Figure 32). Additionally, the reverse bone marrow transplant was also performed,
transplanting ⍺SMA-TK mice with wild-type bone marrow. In order to control for the
influence of irradiation on the wound repair process, additional cohorts of WT and
⍺SMA-TK mice were transplanted from matched donors. As in previous experiments,
mice were wounded and treated with GCV and wound measurements were
performed. Depletion of bone-marrow derived ⍺SMA+ cells did not result in any
significant change in wound closure rate compared to WT mice transplanted with WT
bone marrow with both groups achieving full wound closure by day 16 (Figure 32B).
In contrast, transplantation of wild-type bone marrow into ⍺SMA-TK recipients did not
result in a significant difference in wound closure compared to ⍺SMA-TK mice (Figure
32B). These results suggest that resident, rather than bone marrow derived,
fibroblasts exist as the primary source of ⍺SMA-positive cells within the wound.

65

Donor

A

Recipient

Wound creation

Wild-type
Wild-type

⍺SMA-TK

GCV treatment
and wound
measurement

weeks

Wild-type
⍺SMA-TK
⍺SMA-TK

B
% Wound Area

100

αSMA-TK mice with αSMA-TK BM
αSMA-TK mice with WT BM
WT with αSMA-TK BM
WT with WT BM

50

0

0

2

4

6

8

10

12

14

16

Days Post Wounding
Figure 32. Wild type bone marrow transplantation in ⍺SMA-TK mice did not rescue wound
closure
(A) Schematic diagram of experimental groups. Bone marrow from wild-type or ⍺SMA-TK
donors was transplanted into wild-type or ⍺SMA-TK recipient mice. Three weeks after
transplantation, wound healing experiments were performed, GCV treatment initiated, and
wound measurements performed.
(B) Wound area measurements in wild-type (blue) or ⍺SMA-TK (red) mice transplanted with
wild-type (dashed line) or ⍺SMA-TK (solid line) bone marrow.
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4.C. ⍺SMA+ fibroblasts impair wound closure independently of Gr1+ myeloid
inflammation and TGFβRII mediated signaling
TGFβ1 is recognized as a key cytokine in both fibroblast function and
wound repair. Levels of TGFβ1 are elevated at all stages of wound healing but
typically presents a biphasic pattern peaking transiently during early inflammation and
persistently during later phases of the repair process (104). TGFβ’s role in influencing
wound healing has been considered to be rooted in its function as a promoter of the
myofibroblast phenotype (46). In our model, the increase of several TGFβ family
cytokines and receptors were significantly upregulated at day 6 post-wounding
(Figures 33 and 34), coinciding with the induction of αSMA expression (Figure 10A).
We have previously utilized αSMA-Cre mice harboring a floxed allele of
TGF-beta type II receptor gene (Tgfbr2f/f) and demonstrated that persistent activation
of ⍺SMA+ cells by TGFβ signaling is required to maintain ⍺SMA+ cell populations in
a model kidney fibrosis (41). These mice have been shown to be reproductively viable
and without obvious developmental defects. In order to evaluate the role of sustained
TGFβ signaling on the more transient wound healing system, we utilized these mice
in our full thickness wound healing model. Despite the importance of TGFβ on
inducing and maintaining ⍺SMA expression in fibroblasts, we did not observe any
change in closure rate between ⍺SMA-Cre+ and ⍺SMA-Cre- mice (Figure 35A).
Evaluation of wound tissue collected at Day 14 post-wounding did not reveal any
changes in the quality of the repaired wound (Figure 35B) or collagen deposition as
measured by Masson’s Trichrome Stain (MTS, Figure 35C). These results suggest
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Figure 33. TGFβ family cytokine gene expression in the cutaneous wound repair
process.
Dynamics of TGFβ family cytokines in normal skin (day 0 post-wounding) and wound
tissue from days 3 though 32 post-wounding (n=4 mice per group)
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Figure 34. TGFβ family receptor gene expression in the cutaneous wound repair
process.
Dynamics of TGFβ family receptor in normal skin (day 0 post-wounding) and wound
tissue from days 3 though 32 post-wounding (n=4 mice per group)
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Figure 35. The functional contribution of ⍺SMA+ fibroblasts in wound healing do
not rely on persistent TGFβ signaling
⍺SMA-Cre+ and –Cre- mice were crossed with
(A) Wound closure rates of ⍺SMA-Cre+ TGFβRIIf/f mice compared to ⍺SMACre- littermate controls, n=8 mice per group
(B) Representative H&E images of wounds from Cre+ and Cre- mice at day
17 post wounding
(C) Representative MTS images of wounds from Cre+ and Cre- mice at day
17 post wounding
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that TGFβ type II receptor signaling on ⍺SMA+ fibroblasts is not required for wound
repair.
In order to guide an unbiased determination of the major healing processes
altered by the depletion of ⍺SMA+ cells, we performed gene-expression profiling of
whole wounds from ⍺SMA-TK and WT mice. Because wound closure in ⍺SMA-TK
mice diverged from WT at six days post wounding, we compared enriched gene sets
at days six and seventeen to identify pathways perturbed by the ablation of these cells
(Figure 36). A comparison of ablated and non-ablated wounds demonstrated that
gene profiles in wounds from ⍺SMA-TK mice 17 days post-wounding clustered more
closely with wounds from ⍺SMA-TK or WT day 6 wounds than wild type wounds at
day 17 (Figure 36A). Three gene clusters in particular were significantly altered in
⍺SMA-TK wounds from both time-points compared to wild type mice at Day 6. As
expected based on their inability to re-epithelialize, wounds from ⍺SMA-TK mice
showed a significant reduction in genes associated with hair follicle development,
epidermis, and pigmentation. However, the other major gene clusters associated with
⍺SMA+ cell depletion were associated with inflammation and neutrophil chemotaxis
(Figure 36A). Additionally, gene set enrichment analysis (GSEA) was performed to
identify gene sets commonly up- or down-regulated in Day 6 and Day 17 ⍺SMA-TK
wounds in comparison to Day 6 WT wounds. The most notably enriched gene sets
common to the two groups were the downregulation in Hedgehog signaling pathway
and the WNT signaling pathway. Interestingly, dysregulation of either pathway has
been found to result in impaired wound healing and tissue repair (105-107).
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Figure 36. Global gene expression profiling of wound tissue with and without ⍺SMA+ fibroblasts
depletion
Wound tissue was collected from wounded wild-type (WT) and ⍺SMA-TK mice 6 and 17 days
post-wounding for gene expression profiling.
(A) Heat map rendering and unsupervised clustering of genes differentially expressed between
WT and ⍺SMA-TK mice. n=2 mice per group.
(B) Highly enriched gene pathways in Day 6 ⍺SMA-TK wounds compared to WT controls
based on gene set enrichment analysis (GSEA)
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Based on our microarray analysis, we hypothesized that the arrest in the
healing process observed in ⍺SMA-TK mice was due to an impaired ability of
fibroblasts to restrain or reverse the inflammatory stage of repair. Impaired wound
repair is often associated with an increased inflammatory profile, arresting the healing
process at the late inflammatory stage (108-110). We therefore performed
immunotyping via flow cytometry to determine which immune populations were
affected by ⍺SMA+ cell ablation (Figure 37A). Interestingly, CD4 T-cells, CD8 T-cells,
Natural Killer (NK) cells, NK T-cells, and macrophage populations were not
significantly different in ⍺SMA-TK wounds compared to WT littermates at Day 6 or
Day 17 post wounding. In contrast, granulocytes numbers were significantly elevated
in Day 17 wounds from ⍺SMA-TK mice (24% of viable cells) compared to both Day 17
WT (0.8% of viable cells) and Day 6 ⍺SMA-TK (4.6%) (Figure 37A and B). The
increase in GR-1+ cells in ⍺SMA-TK wounds was further confirmed by quantitative
assessment of immunohistochemistry (Figure 38).
Given the preponderance of evidence for a role of neutrophils in the
development of chronic wounds (111) and their persistence in fibroblast ablated
wounds, we hypothesized that the chronic wound phenotype was a result of a
deficiency in the fibroblast population responsible for restraining neutrophil
accumulation during the repair process. Therefore, we performed antibody depletion
experiments utilizing an anti-Gr-1 antibody on wounded WT and ⍺SMA-TK mice.
⍺SMA-TK and WT mice were wounded and split into two arms, one treated with Gr-1
depleting antibody and the other with IgG control (Figure 39). Both groups began
treatment with GCV at day of wounding. Depletion of Gr-1+ cell populations was
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Figure 37. Immunotyping analyses of wounds with and without ⍺SMA+ fibroblasts depletion
⍺SMA-TK and wild-type control mice were wounded and wound tissue collected at days 6 and 17 postwounding
(A) Percentages of CD4 T-cell, NK cell, Granulocyte, CD8 T-cell, NKT cell, and Macrophage cells in the
indicated experimental groups (n=7 per group)
(B) Representative images of FACS analysis for CD11b-GR-1+F4/80- (granulocyte) cells in wild-type
and aSMA-TK mice 17 days post-wounding
(C) Representative images of FACS analysis for CD11b+GR-1-F4/80+ (macrophage) cells in wild-type
and aSMA-TK mice 17 days post-wounding

74

WT

A

⍺SMA-TK

GR-1

10x

63x

B

*

% Gr-1 Positive Area

3

2

1

0

WT

aSMA-TK

Figure 38. Gr-1+ cells are significantly increased in ⍺SMA+ fibroblasts-depleted
wounds
(A) Immunohistochemical staining for Gr-1 expressing cells in wounds from wildtype and ⍺SMA-TK mice at day 17 post-wounding
(B) Quantification of Gr-1 positive stained area in day 17 wounds from WT and
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Figure 39. Depletion of GR-1+ cells did not rescue the impaired wound closure in ⍺SMA+
fibroblasts-depleted wounds
(A) Schematic diagram of experimental arms. Wild-type and ⍺SMA-TK mice were
wounded and treated with GCV as described previously. Mice were additionally
treated with IgG control or anti-Gr1 antibody to deplete Gr-1+ cells
(B) Wound area measurements in ⍺SMA-TK and WT mice with (dashed lines) or
without (solid lines) Gr-1 depletion antibody treatment.
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confirmed via immunohistochemistry (Figure 40). Contrary to our expectations,
depletion of neutrophils did not result in an improvement of ⍺SMA-TK wound kinetics.
In fact, from Days 2 to 8 post wounding, neutrophil depleted mice showed significantly
less wound closure than IgG controls in both WT and ⍺SMA-TK mice. On day 4 post
wounding, IgG treated WT mice had reduced wound size to 48% of initial wound area,
while aGr1 treated WT mice remained at 67% (Figure 39B). However, by ten days
post wounding the two treatment groups converged. These results would suggest that
the accumulation of neutrophils is a consequence, rather than cause, of the impaired
wound healing phenotype observed in ⍺SMA-tk mice.
One gene which stood out in particular as part of our microarray analysis
was apparent increase IL-6 in ⍺SMA-TK wounds compared to controls. Previous
studies had indicated that loss of IL6 impairs the wound repair process through
delayed wound closure and re-epithelialization, as well as a blunted induction of ⍺SMA
following wounding (112, 113). We first performed rtPCR to confirm the induction of
Il6 gene expression in ⍺SMA-TK wounds (Figure 41A) at days 3 and 6 post-wounding.
On day 3 post wounding IL-6 was increased in wounds from both WT (3.3-fold change)
and ⍺SMA-TK (7.7-fold change) mice compared to normal, unwounded skin. On Day
6, the levels of Il6 in ⍺SMA-TK mice increased 20-fold higher than normal skin, in
comparison to only a 6-fold induction in WT mice (Figure 41A). IL-6 knockout mice
showed impaired, but not halted, wound healing rates (Figure 41B). In IL-6 KO mice,
wound closure rate was reduced at day 4 post-wounding, with WT mice reducing
wound sizes to 45% of initial area while IL-6 KO remained at 62%. Wounds in IL-6 KO
mice did not full close until 22 days post-wounding, in contrast to 14 days in WT mice.
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Figure 40. Confirmation of successful depletion of GR-1+ cells using anti-GR-1
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(A) Representative images of immunolabeling for Gr-1 in wound tissue from WT
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(B) Quantification of the positively stained area for Gr-1 per visual field
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Figure 41. IL-6 production is critical for would healing and is elevated as
compensatory mechanism in ⍺SMA+ fibroblasts-depleted wounds
(A) Gene expression of IL-6 in intact (normal) skin and wound tissue from WT
and ⍺SMA-TK mice at days 3 and 6 following FTS wounding, n=5 mice per
group.
(B) Wound closure rates of IL-6 KO mice compared to wild-type controls, n=5
mice per group
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These results indicate that IL-6 production is critical for would healing and is elevated
as compensatory mechanism when ⍺SMA + fibroblasts are depleted. These findings
offer new insights of the regulatory elements under the control of ⍺SMA+ fibroblasts in
cutaneous would healing.
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Chapter 5. Materials and Methods
5.A. Mice and dermal wound healing
⍺SMA-TK mice, ⍺SMA-RFP, FSP-TK, ⍺SMA-Cre and TGFbR2-floxed mice
have been described previously (41, 100). FAP-TK and Col1a1-TK transgenic mice
were generated in our laboratory by Dr. Toru Miyake. All mice utilized for these
experiments were 8 to 12-weeks old. All procedures were performed according to the
guidelines for BIMDC and MD Anderson.
The full thickness wounding model has been previously described (57,
114). Briefly, two full-thickness wounds were created by a sterile biopsy punch with a
diameter of 8 mm on the shaved bilateral flank of mice. In experiments utilizing the
HSV-TK transgene system, GCV was administered daily at 50mg/kg bodyweight
starting from the day of wound creation until the end of experiment unless otherwise
noted. Wounds were left open and measured by caliper at the indicated time points.
The wound areas (percentage of wound areas to initial) were calculated from the
formula length x width x 0.7568. Skin with the wound was removed for further
experiments.
For bone marrow transfer experiments, bone marrow was harvested from
the tibia and femur of WT, ⍺SMA-tk and ⍺SMA-RFP donor mice. A single cell
suspension was performed. Recipient Balb/c mice were irradiated with 800cGy Co60
source. Approximately 5 x 105 cells in PBS were injected into different sex mice via
retro-orbital vein. 3 weeks after transplantation, wound healing experiments were
performed. Degree of chimerism were assessed by FISH for the Y-chromosome as
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previously described (41).
5.B. Fibroblasts culture
Ex vivo culture and GCV treatment of ear fibroblasts was carried out as
previously described (41, 95). Briefly, ears were collected from WT and TK+ mice and
digested using collagenase for 24 hours. Cells were then expanded in culture for no
more than two weeks before being seeded to 96 well plates at 1x104 cells per well
and treated with GCV at concentrations of 0, 5, and 50uM. After a treatment period of
three days, cell viability was measured using trypan blue exclusion.
5.C. Immunolabeling and antibodies
For tissues for immunohistochemistry staining, harvested tissues were
fixed in 10% formalin and embedded in paraffin. 5um sections were rehydrated and
antigen retrieval was performed using 10mM citrate buffer (pH 6.0) for 15min to 1
hour. After 1 hour blocking with blocking buffer, sections were incubated with primary
antibody overnight at 4°C. Following incubation with secondary antibody for 1 hour at
room temperature and ABC reagent (Vector Laboratory, West Grove, PA). The
sections were developed by DAB staining.
For frozen tissue sections, 8μm sections from OCT embedded tissues were
fixed with 4% PFA for 20 min and incubated with 0.3% triton-X for 30 min. after
blocking with blocking buffer, sections were incubated with primary antibody overnight
at 4°C. This was followed by incubation with secondary antibody for 1 hour at room
temperature and stained with DAPI or DRAQ5 for 30 min. Unless otherwise noted, all
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analysis of positive cell number or signal intensity was limited to the wound granulation
tissue. Number of positive cells identified by immunohistochemistry was quantified
using the Adobe Photoshop count tool. Mean positive area was quantified using
ImageJ.
Antibodies used in this study: ⍺SMA (Dako, M0851), FSP1/S100A4 (Dako,
A5114), Collagen 1 (Southern Biotech, 1310-01), DDR2 (Santa Cruz, sc-7555), FAP
(Abcam, ab53066), Vimentin (Cell Signaling Technologies 5741S), Ki67 (Thermo
Fisher, TM-9106-S), CD31 (Dianova, DIA310), and Sca-1 (BD Pharmingen, 557403).
5.E. Gene expression analyses
RNA was isolated from snap frozen tissue and extracted using Trizol. cDNA
was synthesized using High-Capacity cDNA Reverse Transcription Kit. Real-time
quantitative PCR was carried using SYBR Green Real-Time PCR Master Mixes on
QuantStudio™ 7 Flex Real-Time PCR System from ThermoFisher.

5.F. in situ hybridization
In situ hybridization (ISH) was performed on frozen wound tissue sections
using standard methods (96). Briefly, 8μm sections from OCT embedded tissues were
post-fixed with 4% PFA, acetylated with 1% triethanolamine and 0.25% acetic
anhydride, pre-hybridized, then hybridized with Col1a1 probe overnight at 60°C.
Following hybridization sections were incubated with anti-DIG antibody (1:3000,
Roche) for 90 minutes. After washes, sections were incubated with BM Purple (Roche)
and counterstained with Nuclear Fast Red.
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5.G. Atomic Force Microscopy
Atomic Force Microscopy was conducted at the UT-Health Science Center
AFM Core Facility using a BioScope IITM Controller (Bruker Corporation; Santa
Barbara, CA). The image acquisition was performed with the Research NanoScope
software version 7.30 and analyzed with the NanoScope Analysis software version
1.40 (copyright 2013 Bruker Corporation). This system was integrated to a Nikon
TE2000-E inverted optical microscope (Nikon Instruments Inc.; Lewisville, TX) to
facilitate bright field imaging of the tissue sections.
To investigate the nano-mechanical properties of the tissue surface, skin
wound samples were obtained from ⍺SMA-TK and wild type mice. Tissue cryosections
of 40 µm in thickness were attached to glass microscope slides pretreated over night
with poly-L-lysine (0.1% (W/V) Sigma P8920) at room temperature to enhance tissue
attachment. The Elastic (Young’s) Modulus was measured on hydrated tissue
sections using DNP-S triangular cantilevers (fo=12-24 kHz, k=0.06 N/m, ROC=10nm)
purchased from Bruker Corporation (Santa Barbara, CA). Wound areas of the tissue
sections were selected with the aid of optical microscopy. Force Volume images were
captured on 50 µm2 scan areas with 16 x 16 force measurements per line. Force
curves were probed using a ramp size of 2 µm and a scan rate of 1.0 Hz, with a force
load of 15 nN. The probe spring constant was determined prior to each experiment
using thermal tuning. The Elastic modulus was calculated by fitting to a standard
Sneddon model for a conical indenter and a Poisson’s ratio of 0.5. At least, 3 areas
were analyzed for every tissue sample in the skin wound. A minimum of 256 force
measurements were captured for each area.
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AFM topographical imaging was performed on dry tissue sections using
RTESP cantilevers (fo=237-289 kHz, k=20-80 N/m, Bruker Corporation, Santa
Barbara, CA). The structure of the tissue was determined using tapping mode
operated in air to a scan rate of 0.7 Hz. Images of the fibroblasts deposition were
captured to a scan range of 10, 5, and 2.5 µm2.
5.O. Immunohistochemical multiplex
The process for multiplexed staining and imaging has been previously
described (89). Briefly, 5μm sections of paraffin embedded tissue were deparaffinized
and subjected to antigen retrieval with heated Citric Acid Buffer (pH 6.0) for 15 min
(EZ Retriever microwave, BioGenex). Each section was put through sequential rounds
of staining, each including a protein block with 1% BSA, primary antibody, secondary
horseradish peroxidase-conjugated polymer, and a different fluorophore using
tyramide signal amplification. This was followed by additional antigen retrieval in
heated Citric Acid Buffer (pH 6.0) for 15 min to remove bound antibodies before the
next step in the sequence. Sections were then counterstained with DAPI and mounted
with Fluoroshield histology mounting medium (Sigma-Aldrich, St. Louis, MO). Stained
slides were imaged using the Vectra Multispectral Imaging System version 3 (Perkin
Elmer) at 200x magnification. A spectral library was then used (spectral unmixing)
allowing for the colour-based identification of all six markers of interest in a single
image using the inForm 2.3 image analysis software.
5.G. Multispectral imaging analyses
To quantitatively analyze changes in cell populations during would healing,
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we utilized a proprietary active learning algorithm provided by the Perkin Elmer Inform
image analysis software package. This system was used to perform cell and tissue
segmentation on acquired images. Tissue segmentation allows the definition of tissue
compartments based on trainable features. Further, cell segmentation allowed us to
identify marker-assigned fluorescent signal and coordinates for each individual cell. A
threshold value of signal intensity to define marker positivity was experimentally
determined for each marker investigated.
In order to perform quantitative analysis of the entire wound bed, cells
and/or images acquired were merged. Cells and mosaic images were plotted on an
XY coordinate plane based on identified coordinates during cell segmentation. Wound
edge coordinates were defined based on morphological features (thickened
epidermis, loss of hair follicles, accumulation of cells expressing myofibroblast
markers). Cells in non-dermal regions or those outside the region defined by the two
edges were not analyzed. Utilizing the R Statistical Computing platform, each cell
within this region was defined as positive or negative based on fluorophore signal
intensity above the thresholds defined above. A truth table containing the relative
proportion for each identified phenotype was compiled using the R QCA package
(CRAN).
The coordinates between these two experimentally defined wound edges
was averaged to identify a wound center. Distance of each cell within the dermal layer
of the wound bed from the closest wound edge was determined by calculating the
length of a perpendicular line representing the shortest distance between the cell and
wound edge line.
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5.H. Statistical analyses
All statistical analyses were performed using the GraphPad Prism software
unless stated otherwise. Statistical analyses of immunohistochemical quantifications
were performed using a Student’s t-test, Mann-Whitney test or analysis of variance as
appropriate. Data are represented as the mean ±SEM. *p < 0.05, **p < 0.01, ****p <
0.0001. ns, not significant.
5.Q. Microarray analysis
For microarray analyses, total wound RNA (500 ng) was used for labeling
and hybridization according to the manufacturer's protocols (Illumina, Inc, San Diego,
CA) using the Illumina MouseWG-6 v2.0 expression BeadChips. The BeadChips were
scanned with Illumina BeadArray Reader (Illumina, Inc). The results of microarray data
were extracted with Bead Studio 3.7 (Illumina, Inc.) with background subtraction.
Gene expression data were normalized using quantile normalization method in LIMMA
package in R. The expression level of each gene was transformed into log2 before
further analysis. To avoid potential false-positive genes because of technical variance,
all experiments were carried out in quadruplicate.
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Chapter 6. Discussion
Fibroblasts in the dermis are mesenchymal cells chiefly considered to
function in the maintenance of skin through to production of ECM. However,
fibroblasts are now postulated to orchestrate tissue repair by interacting with and
controlling other cell types, including immune cells, in the wound microenvironment. It
has become increasingly clear that the generic term “fibroblast” encompasses a
diverse cell population with distinct origins and heterogeneous functions. Fibroblast
heterogeneity is in part exemplified by the numerous expression markers used to
distinguish them. Both between and within anatomical locations, fibroblasts have been
shown to present distinct marker phenotypes and gene expression profiles (51, 94,
115-117). However, the diversity of dermal fibroblasts and their dynamic contribution
to the process of wound healing remain poorly understood. The overarching goal of
this study was to define the heterogeneity of dermal fibroblasts and unravel their
functional roles during cutaneous wound healing process.
Despite the numerous markers utilized to identify fibroblasts, few studies
have worked to characterize the fibroblast composition identified using these markers.
As fibroblasts, especially in repairing tissue, are not amenable to flow cytometry or ex
vivo culture without introducing a selective pressure (118), research has relied on the
laborious use of histological examination of serial tissue sections (51, 57). In this
study, we have made use of Tyramine Signal Amplification (TSA)-based
immunolabeling and multispectral imaging in order to evaluate the abundance and
distribution of three commonly utilized fibroblast markers during wound repair. This
technique offered several benefits over previous techniques: (A) By performing
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multiplexed labeling on a single section, we avoided the loss of cells and
morphological features which can occur even with serial sectioning. (B) Histological
studies have often been limited by the potential bias introduced by examining cells
only within a representative region of the tissue. In the work presented here,
evaluation of fibroblast heterogeneity was carried out throughout the entirety of the
repairing dermis. (C) Using computational tissue segmentation, we were able to limit
our study to evaluation of the repairing dermis without the influence of putative
fibroblast marker expression in non-fibroblast populations. We made use of these
computational tissue and cell segmentation techniques in order to provide a more
complete picture of acquisition of fibroblast markers during repair. The use of
computational algorithms not only provides an unbiased quantification method, but
also one that can readily scale up to the tens of thousands of individual cells within a
single tissue, or millions of cells within an experimental cohort. Using this system, we
were able to systematically probe the abundance and distribution of fibroblasts within
the repairing dermis to a higher degree than was previously possible.
Interestingly, this approach unraveled a significant progression of marker
expression, from FSP-1+ fibroblasts found dominantly in the intact skin, to principally
⍺SMA+ fibroblasts by Day 6 following wounding, followed by an increase in Vimentin+
cells during the final stages of wound re-epithelialization and maturation. The changes
in fibroblast marker composition we observed during wound repair did not appear to
be exclusively due to proliferation of existing populations. Instead, when colocalization of multiple markers was taken into account, it suggested that the observed
changes in fibroblast markers rather represent an evolution in the marker expression
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of fibroblasts. Of particular note was the expansion in the FSP-1/S100A4 and αSMA
double positive population observed at day 6 post-wounding, leading us to the
hypothesize that αSMA+ fibroblasts arise from FSP1/S100A4+ progenitors. Using
FSP-Cre reporter mice, we found that at this time-point 35% of αSMA+ fibroblasts had
at some point expressed FSP-1/S1004. Although FSP-1/S100A4 was originally
considered a pan-fibroblast marker (54), more recent work has suggested that FSP1/S100A4 may identify a distinct population from αSMA+ fibroblasts in some models
(51, 119-121). In 2006, Sugimoto et al. investigated the co-localization of αSMA and
FSP-1/S100A4 expression in the 4T1 model of breast cancer and the Rip1-Tag2
model of pancreatic cancer. In the 4T1 model only 10.9% of αSMA+ cells also
expressed FSP-1/S100A4. In contrast, 43.5% of αSMA+ cells in the Rip1-Tag2 model
co-expressed FSP-1/S100A4. In a study using a murine lung fibrosis model, it was
found that although FSP-1/S100A4 had no overlap with αSMA expressing cells, they
did sometimes co-localized with Vimentin and CD45 (119). Together, these results
suggest that a portion of αSMA+ fibroblasts, but not all, arise from FSP-1/S100A4
positive cells.
The markers used to identify fibroblasts in this study do not cover the
entirety of proposed markers in the literature, particularly given their heterogenous
origins. New techniques employing imaging mass cytometry allow examination of over
100 markers in a single slide (122, 123). Combining these new imaging technologies
with the analysis method developed as part of the presented study will not only allow
even more comprehensive analysis of fibroblast evolution during tissue repair as well
as exclusion of non-fibroblast populations that have acquired fibroblast phenotypes.
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In our work, we controlled for the expression of mesenchymal markers in endothelial
cells by removing all CD31+ cells from our analysis of fibroblast heterogeneity.
However, immune cells, in particular macrophages, have been found to express
putative fibroblast markers such as FSP-1/S100A4 and FAP (124-126). Expanding
the number of markers evaluated to include populations such as immune cells, hair
follicle stem cells, and epithelial cells will further allow us to probe the association
between fibroblasts and these different cell types (89).
The importance of analyzing the dermis apart from other parts of the skin
is highlighted by findings demonstrating the expression of commonly regarded
fibroblast markers by other cell populations. Within the epidermis, there is existing
evidence that during wound repair keratinocytes may acquire expression of FSP1/S100A4 and Vimentin, presumably through TGFβ induced EMT signaling (127). Our
own histological examination and lineage-tracing of FSP-1/S100A4+ cells agrees with
this. Further, lineage tracing experiments have suggested that subdermal preadipocytes may contribute to the pool of αSMA+ fibroblasts during wound repair (63),
and that conversely myofibroblasts may differentiate into adipocytes following
wounding (128). In the latter study, the conversion of myofibroblasts into adipocytes
relied on BMP signaling by regenerated hair follicles. Although we did not observe a
loss of adipose tissue in our αSMA-TK experiments, this is reasonable given the
wounds inability to re-epithelialize. Additionally, hair follicle regeneration in murine
models has only been described following repair of very large wounds (1.5-2cm2),
roughly three to six times the surface area of the wounds generated in our experiments
(129).
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The question remained whether identification of fibroblasts by marker
composition is reflective of their biological role in normal and disease states. This is a
question explored not only in the realm of wound repair, where the division between
papillary and reticular fibroblasts has been heavily studied, but also studies
investigating fibrosis (41) or the tumor microenvironment (94, 95). Many studies
attempting to characterize the functional role of fibroblast subpopulations on wound
healing have relied on in vitro expansion and measurement of cytokine or gene
expression measurements from cultured cells. These studies are necessarily limited
by ignoring the complex interactions between fibroblast cells with other cells of the
wound microenvironment (immune, epidermal, adipose, etc) as well as the potential
for alterations in gene expression resulting from in vitro culture. To address the
functional contribution of fibroblast populations on wound healing, we targeted
fibroblasts using mice expressing viral thymidine kinase (HSV-TK) under fibroblastspecific promoters. In contrast to diphtheria toxin receptor-mediated targeted ablation
(130), this model allows the selective depletion of proliferating fibroblasts as found in
the repairing wound. Due to the ubiquity of fibroblasts throughout the body, targeting
only proliferating cells is likely to result in fewer unintended side-effects. In the work
presented here, utilization of the HSV-TK model targeting four specific markers
(αSMA-TK, FSP1-TK, FAP-TK, Col1a1-TK) presented four distinct phenotypes.
Depletion of αSMA+ fibroblasts during the wound closure process resulted
in a complete inability for wounds to re-epithelialize by six days post wounding,
producing wounds with significantly lower collagen and re-vascularization than wildtype controls. αSMA+ cells were depleted to a comparable degree as what our
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laboratory has previously observed in the unilateral ureteral obstruction (UUO) renal
interstitial fibrosis model (41). Also, in contrast to the studies in renal fibrosis models,
few of the αSMA+ fibroblasts within the wound were derived from the bone marrow, in
comparison to 35% in the UUO model. Most interestingly, genetic deletion of TGFβ
receptor 2 in αSMA expressing cells did not result in an observable phenotype with
respect to wound closure or collagen deposition. In contrast, studies deleting the
TGFBR2 gene locus in Collagen1a2 expressing cells resulted in faster reepithelialization and reduced collagen deposition (131, 132). TGFβ is known to be a
potent inducer of αSMA and collagen, and this has led research into modulation of
TGFβ as potential method to reduce scarring (71, 87, 133-135). It is possible that while
TGFβ is necessary for the initial activation of the myofibroblast phenotype, it is not
required for the maintenance of that state in the timeframe of our studies. Future
studies investigating the role of TGFβ signaling on wound healing fibroblasts may
benefit from the use of a population which exists before stimulation with TGFβ.
Although FSP-1/S100A4 would be an attractive option given our described results in
Chapter 2, interpretation of results would require the caveat that FSP-1/S100A4 was
also found to be expressed in the epidermis.
In contrast, targeted depletion of FSP-1/S100A4+ cells using the FSP1-TK
mouse model resulted in a statistically significant but less pronounced depletion of the
targeted cell population. These FSP1-TK mice showed no phenotypic difference
compared to wild-type controls with regards to wound closure rates or histological
assessments. In comparison, depletion using these mice in the UUO setting resulted
in a 75% decrease in FSP-1/S100A4+ cells with a resulting significant decrease in
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both fibrotic area and collagen deposition within the fibrotic kidney (100). These results
are counterintuitive given our finding that FSP-1/S100A4+ cells in wounds displayed a
higher proliferation rate than αSMA+ cells at all time-points examined. These data
suggest that fibroblasts identified by FSP-1/S100A4 may either rapidly transition to
αSMA+ myofibroblasts during early phases of healing,or represent a transition of
fibroblasts expressing other markers to FSP-1/S100A4+ following re-epithelialization.
Targeted depletion of FAP+ or Collagen1 producing cells resulted in a significant
decrease in the targeted cell population but did not impair wound closure to the degree
identified in αSMA-TK mice. Despite a significantly decreased wound closure rate,
FAP-TK mice demonstrated an increased collagen within their granulation tissue.
Although not evaluated in this study, previous work in fibrosis models have implicated
FAP mediated signaling in collagen degradative pathways (136, 137). Depletion of
Collagen1 producing cells resulted in a significant increase in vascularization,
measured by CD31+ cell number, as well as an increased hypoxic area compared to
control mice. These results appear at first contradictory, but it is possible that
Collagen1a1+ cells are responsible in part for the maturation of the vasculature during
wound repair, as has been suggested in the case of bone marrow derived MSCs (138).
One potential weakness in the use of the thymidine kinase cell depletion model is that
only proliferating cells are targeted. Despite the significant depletion quantified in our
studies a portion of each population remained, and a direct link between expression
of a fibroblast population and its function within the repairing dermis is thus hampered
by our inability to fully deplete specific populations at arbitrary time-points. Although
some studies have attempted to employ genetic deletion of fibroblast markers, as has
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been performed with Vimentin knockout (139), DDR2 knockout (140), and αSMA
knockout mice (141), these studies are limited by the fact that deletion of a gene does
not necessarily result in loss of the underlying phenotype. Further, genetic knockout
may not aid the questions asked in this study due to intracellular signaling pathways
altered by deletion of these genes (139, 140) and compensation by functionally related
genes (141).
A caveat in translating our findings to actionable treatments in human
patients lies in the differences in human and murine wounds. Although mice are by far
the most commonly used for biologic research, there exist differences between the
skin of mice and humans (21, 142). In particular, murine skin has a thin muscle layer
lying beneath the dermis which produces the rapid wound contraction seen during the
initial days of the repair process. Experimental approaches to counter this initial
contraction include the splinted wound model (143) and sponge implantation model
(144). These models however come with their own caveats, primarily due to the
immune response generated by implantation of foreign objects. As a result, the use of
the full thickness excisional wounding model remains the most commonly utilized
model in the study wound healing.
In summary, the findings presented in this study present evidence for both
the heterogeneity of fibroblast marker expression during the wound repair process but
also heterogeneous functional roles. Investigation of fibroblast marker expression at
multiple time points during repair indicated that while in normal skin FSP-1/S100A4+
fibroblasts are the predominant population, there is a transition of at least part of these
cells to acquire the myofibroblast phenotype characterized by expression of αSMA.
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When fibroblast populations were depleted based on marker expression, distinct
phenotypes could be observed in terms of wound closure rate and quality of the healed
wound bed. In particular, depletion of αSMA+ fibroblasts resulted in a complete inability
to re-epithelialize. Interestingly, despite an increased number of granulocytes found in
αSMA depleted wounds, depleting these cells using antibody depletion did not reverse
the αSMA-TK phenotype. As a result, these findings suggest that the primary function
of αSMA+ fibroblasts is in supporting wound re-epithelialization.
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